Recent developments focus on Evolent Health's Q3 2026 financial results and earnings call disclosures, highlighting operational performance and financial metrics.

• Evolent Health reported third quarter 2026 financial results including a net loss and EPS of -$0.21 per share [N2].
• The company matched Q3 earnings estimates as discussed in the earnings call transcript [N3][N4].
• Key financial metrics for Q3 2026 were reviewed in detail, providing insights into revenue and expense trends [N5].
• The Q3 2026 earnings call included management commentary on business performance and strategic initiatives [N1].

The company demonstrates operational transparency through detailed SEC filings and regular earnings call disclosures. Its liquidity ratios indicate a capacity to meet short-term obligations, and ongoing corporate transactions suggest active strategic management. The availability of comprehensive financial data and governance disclosures supports a clear understanding of its business model and financial health.

Evolent Health reported a net loss in the most recent quarter, indicating challenges in profitability. The cash ratio of 0.3 suggests limited immediate cash coverage relative to current liabilities. The company operates in a complex regulatory environment requiring ongoing compliance and governance vigilance. Risks inherent in healthcare sector dynamics and integration of acquired assets may impact operational consistency.

Evolent Health's moat is supported by its established relationships and contracts in the healthcare sector, as evidenced by multiple asset purchase agreements and mergers disclosed in SEC filings. The company's compliance with regulatory requirements and transparent governance practices, including a publicly posted Code of Business Conduct and Ethics, contribute to its operational stability. Its liquidity position and access to credit facilities provide financial flexibility to support ongoing operations and strategic initiatives.

• Profitability Risk: The company reported a net loss of $23.6 million for Q3 2026, reflecting ongoing challenges in achieving profitability.
• Liquidity Risk: With a cash ratio of 0.3 as of September 30, 2026, the company has limited cash coverage for current liabilities, which may constrain operational flexibility.
• Regulatory and Compliance Risk: Evolent Health operates in a heavily regulated healthcare environment requiring strict adherence to laws and governance codes, with potential risks from regulatory changes or compliance failures.
• Integration Risk: The company has engaged in multiple acquisitions and asset purchases, which may pose risks related to integration and realization of expected benefits.

• Evolent Health, Inc. is a publicly traded company with ticker EVH.
• The company files regular SEC reports including 10-K annual and 10-Q quarterly filings, with the latest 10-Q filed on 2026-11-05 covering the period ending 2026-09-30 [S2].
• As of September 30, 2026, Evolent Health reported cash and cash equivalents of $148.3 million and current assets of $617.1 million against current liabilities of $489.9 million, resulting in a current ratio of 1.26 and a cash ratio of 0.3 [S2].
• The company reported a net loss of $23.6 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.21 per share [S2].
• Annual revenue reported for fiscal year 2023 was approximately $556.1 million [S1].
• Evolent Health provides earnings call transcripts and financial results summaries regularly, with recent Q3 2026 earnings call and financial results publicly available [N1][N2][N3][N4][N5].
• The company has a Code of Business Conduct and Ethics applicable to all directors, officers, and employees, disclosed in its 2026 10-K filing [S1].
• Evolent Health has executed multiple asset purchase agreements and mergers as disclosed in SEC filings, indicating active corporate transactions [S1].
• The company maintains a revolving credit agreement and has amended it multiple times, with details disclosed in recent SEC filings [S1].
• Recent news coverage includes detailed Q3 2026 earnings call highlights and financial results reported by primary sources such as Nasdaq [N1][N2][N3][N4][N5].